These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 2033514)
1. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514 [TBL] [Abstract][Full Text] [Related]
2. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147 [TBL] [Abstract][Full Text] [Related]
3. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. Giovanni A; Sonsalla PK; Heikkila RE J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148 [TBL] [Abstract][Full Text] [Related]
4. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline. Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. Sonsalla PK; Youngster SK; Kindt MV; Heikkila RE J Pharmacol Exp Ther; 1987 Sep; 242(3):850-7. PubMed ID: 2888874 [TBL] [Abstract][Full Text] [Related]
6. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity. Zuddas A; Fascetti F; Corsini GU; Piccardi MP Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437 [TBL] [Abstract][Full Text] [Related]
9. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs. Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564 [TBL] [Abstract][Full Text] [Related]
10. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. Di Monte DA; Wu EY; Irwin I; Delanney LE; Langston JW J Pharmacol Exp Ther; 1991 Aug; 258(2):594-600. PubMed ID: 1907660 [TBL] [Abstract][Full Text] [Related]
12. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuroblastic apoptosis in the subventricular zone is caused by 1-methy-4-phenylpiridinium (MPP(+)) converted from MPTP through MAO-B. Ito T; Suzuki K; Uchida K; Nakayama H Exp Toxicol Pathol; 2012 Nov; 64(7-8):761-5. PubMed ID: 21324658 [TBL] [Abstract][Full Text] [Related]
13. Involvement of monoamine oxidase-B in the acute neurotoxicity of MPTP in embryonic and newborn mice. Sai T; Uchida K; Nakayama H Exp Toxicol Pathol; 2013 May; 65(4):365-73. PubMed ID: 22281418 [TBL] [Abstract][Full Text] [Related]
14. Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites. Itzhak Y; Mash D; Zhang SH; Stein I Mol Pharmacol; 1991 Mar; 39(3):385-93. PubMed ID: 1848660 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs. Youngster SK; Nicklas WJ; Heikkila RE J Pharmacol Exp Ther; 1989 Jun; 249(3):829-35. PubMed ID: 2786565 [TBL] [Abstract][Full Text] [Related]
16. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. Riachi NJ; Harik SI; Kalaria RN; Sayre LM J Pharmacol Exp Ther; 1988 Feb; 244(2):443-8. PubMed ID: 3258032 [TBL] [Abstract][Full Text] [Related]
17. Differences in the disposition and toxicity of 1-methyl-4-phenylpyridinium in cultured rat and mouse astrocytes. Tsai MJ; Lee EH Glia; 1994 Dec; 12(4):329-35. PubMed ID: 7890335 [TBL] [Abstract][Full Text] [Related]
18. Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. Di Monte DA; Wu EY; Delanney LE; Irwin I; Langston JW J Pharmacol Exp Ther; 1992 Apr; 261(1):44-9. PubMed ID: 1560384 [TBL] [Abstract][Full Text] [Related]
19. Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes. Di Monte DA; Wu EY; Irwin I; Delanney LE; Langston JW Glia; 1992; 5(1):48-55. PubMed ID: 1311704 [TBL] [Abstract][Full Text] [Related]
20. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. Chan P; Langston JW; Di Monte DA J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]